144 related articles for article (PubMed ID: 36940681)
1. Sex-Specific Differences in the Risk of Heart Failure following Anti-HER2 Monoclonal Antibody Therapy.
Suzuki Y; Kaneko H; Tamura Y; Okada A; Michihata N; Jo T; Takeda N; Morita H; Fujiu K; Node K; Yasunaga H; Komuro I
Oncology; 2023; 101(6):358-361. PubMed ID: 36940681
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
Banke A; Fosbøl EL; Ewertz M; Videbæk L; Dahl JS; Poulsen MK; Cold S; Jensen MB; Gislason GH; Schou M; Møller JE
JACC Heart Fail; 2019 Mar; 7(3):217-224. PubMed ID: 30819377
[TBL] [Abstract][Full Text] [Related]
3. The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis.
Wu WC; Huang CC; Tsai YF; Lin YS; Feng CJ; Chen YJ; Lai JI; Chao TC; Liu CY; Tseng LM
Breast Cancer Res Treat; 2023 Feb; 198(1):113-122. PubMed ID: 36586037
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor.
Simonds HM; Miles D
Expert Opin Biol Ther; 2007 Apr; 7(4):487-91. PubMed ID: 17373900
[TBL] [Abstract][Full Text] [Related]
6. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
Cobleigh MA; Vogel CL; Tripathy D; Robert NJ; Scholl S; Fehrenbacher L; Wolter JM; Paton V; Shak S; Lieberman G; Slamon DJ
J Clin Oncol; 1999 Sep; 17(9):2639-48. PubMed ID: 10561337
[TBL] [Abstract][Full Text] [Related]
7. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
Chen J; Long JB; Hurria A; Owusu C; Steingart RM; Gross CP
J Am Coll Cardiol; 2012 Dec; 60(24):2504-12. PubMed ID: 23158536
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
9. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
10. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.
Seicean S; Seicean A; Alan N; Plana JC; Budd GT; Marwick TH
Circ Heart Fail; 2013 May; 6(3):420-6. PubMed ID: 23425978
[TBL] [Abstract][Full Text] [Related]
12. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G
Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400
[TBL] [Abstract][Full Text] [Related]
13. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
15. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
Dawood S; Broglio K; Buzdar AU; Hortobagyi GN; Giordano SH
J Clin Oncol; 2010 Jan; 28(1):92-8. PubMed ID: 19933921
[TBL] [Abstract][Full Text] [Related]
16. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
[TBL] [Abstract][Full Text] [Related]
17. Sex-Specific Epidemiology of Heart Failure Risk and Mortality in Europe: Results From the BiomarCaRE Consortium.
Magnussen C; Niiranen TJ; Ojeda FM; Gianfagna F; Blankenberg S; Vartiainen E; Sans S; Pasterkamp G; Hughes M; Costanzo S; Donati MB; Jousilahti P; Linneberg A; Palosaari T; de Gaetano G; Bobak M; den Ruijter HM; Jørgensen T; Söderberg S; Kuulasmaa K; Zeller T; Iacoviello L; Salomaa V; Schnabel RB;
JACC Heart Fail; 2019 Mar; 7(3):204-213. PubMed ID: 30819375
[TBL] [Abstract][Full Text] [Related]
18. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes.
Gong IY; Yan AT; Earle CC; Trudeau ME; Eisen A; Chan KKW
Breast Cancer Res Treat; 2020 May; 181(1):155-165. PubMed ID: 32236828
[TBL] [Abstract][Full Text] [Related]
20. Proteinuria and Risk for Heart Failure in 55,191 Patients Having History of Cancer.
Suzuki Y; Kaneko H; Okada A; Fujiu K; Michihata N; Jo T; Takeda N; Morita H; Kamiya K; Matsunaga A; Ako J; Node K; Nangaku M; Yasunaga H; Komuro I
Am J Nephrol; 2022; 53(10):753-760. PubMed ID: 36543162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
